We are a passionate team of advocates for revolutionary advances in medical technology.
Board of Directors
Donald V. Almeida, Lead Director/Chair
Donald Almeida was the Vice Chairman for PwC. In this role, he was responsible for PwC’s global clients, markets, and industries.
Almeida also was client service vice chairman for the U.S. firm and managing partner for several U.S. industry groups, including technology, infocom, and entertainment and media. In addition to these management roles, he served as a member of the U.S. Board of Partners and the PwC Global Board of Partners.
Almeida has 40 years of career experience, principally with large multinational companies and in market-facing leadership roles. He also has extensive experience abroad, in particular in Brazil, Russia, India, China, Japan, and most of Europe, including a three-year tour in Italy.
Almeida is on the board of APOS Therapy and WellDoc and formerly on the board of Trxade. He is also on the advisory boards of Talent Box and Namu. In addition he is on the boards of Trustees of Fordham University, The Marinsky Foundation of America, Cardinal Hayes HS, and the Boy Scouts of America. He is also on the Fordham Gabelli School of Business Board, the Fordham Presidents council and is an adjunct professor and quest lecturer on Global Business , Entrepreneurship and other topics
Almeida is a member of the American Institute of Certified Public Accountants and is licensed in New York and Connecticut. He holds a BS degree in accounting from the Gabelli School and lives in Armonk, New York, with his wife, Gail, and his two children.
An active investor in early stage private companies in the life sciences and big data sectors, Juan is one of the world’s leading authorities on the uses and benefits of genomic code. He is the co-author of Evolving Ourselves: How Unnatural Selection and Nonrandom Mutation are Shaping Life on Earth (Penguin; March 2015) which describes a world where humans increasingly shape their environment, themselves, and other species. He is also the author of the global bestseller As The Future Catches You and of The Untied States of America, and co-author of Homo Evolutis. Juan writes, speaks, and teaches about the profound changes that genomics and other life sciences will cause in business, technology, politics and society. He is one the TED all-stars. He and Bill Gates were the first outside guest curators for TED. He was the founding director of the Harvard Business School Life Sciences Project and is on the Harvard Medical School Advisory Council. He has published papers and articles in a wide variety of forums including The Harvard Business Review, Foreign Policy, Science, Nature, and the New York Times.
David Levy, MD
David Levy has been a champion of patient-centric medicine and the use of technology to disrupt and improve healthcare delivery. As the Global Healthcare Leader, he forged global alliances and developed new business and delivery models for PwC's clients. Under Dr. Levy's leadership, PwC developed a particular focus on mobile health technology and its vast potential in emerging markets.
Dr. Levy began his career as a primary care physician and epidemiologist, successfully founding a large primary care practice in suburban New York City. As a quality consultant for large health insurers, he saw the opportunity to rethink how complex patients were treated in the US healthcare system and created Franklin Health Group, one of the nation's first disease management companies, and led it through a successful acquisition to a global point-of-care diagnostics company.
In his current role, serves as Global CEO of AposTherapy, a global device company. He currently sits on the boards of Welldoc, SulAmerica, the largest multi-line insurer in South America, the United Hospital Fund of New York, Cedar Gate Technologies, and AposTherapy.
As CEO, Kevin has led the WellDoc® team in the successful launch and continued development of the digital therapeutic for people living with type 2 diabetes, BlueStar®. Under his leadership, WellDoc has expanded its suite of BlueStar products to include: BlueStar® Rx, BlueStar® and BlueStar® C. Kevin oversees all WellDoc business related to enterprise strategy and has engineered an innovative commercial approach to position BlueStar in the marketplace to attract key investors and partnerships that include, Johnson & Johnson, Samsung and Merck GHI. He has been instrumental in positioning WellDoc as the leading digital health company in the development of digital therapeutics.
Prior to joining WellDoc in 2014, Kevin had an extensive career in biotech and pharmaceuticals. He held senior commercial roles at Human Genome Sciences, Genentech and Abbott after beginning his career at Baxter Healthcare.
Dave Stevenson is Managing Director of Merck Global Health Innovation (GHI) Fund. Dave brings over 20 years of healthcare strategy and innovation expertise to the GHI team. In addition, Dave also brings a strong operational focus to accelerating value realization for portfolio companies. Prior to joining the Global Health Innovation Fund, Dave has been a member of Merck's Strategy Office focused on corporate strategy development, including whitespace identification, scenario planning, and transformational business model development. Prior to joining Merck Dave spent a decade in strategy consulting helping small and large health care companies find new growth drivers while freeing up cash flows from operations to fund higher value added activities. Dave started his career with strong cross-functional operating roles with Novartis, including deep experience in Clinical Development and Commercial Operations. Dave holds a BA from Washington University and a MBA from Vanderbilt University.
Hyuk-Jeen Suh is the Head of the Samsung Ventures East Coast office bringing over 20 years of industry experience in consumer electronics, biotech, and semiconductor. Before joining Samsung Ventures, Hyuk-Jeen worked at J.P. Morgan investment banking in the Technology, Media, and Telecom group. Prior to J.P. Morgan, he was the global senior business development and marketing manager at MEMSIC, a semiconductor startup with clients in the automobile and consumer electronics industry. He led the global marketing strategy which contributed to the successful IPO of MEMSIC in 2007. Prior to joining MEMSIC, Hyuk-Jeen was a senior research engineer at Sequenom, a biotech startup. He conducted research on DNA biochips and led joint venture projects with Hitachi and Samsung to design high-throughput bio instruments. He began his career at Intel Corporation as a process engineer, leading yield improvement projects which contributed to one of the highest yield rates in Intel history for the Pentium microprocessor. He advises startup companies and is a mentor at various startup accelerators. He is a guest speaker at universities including Harvard University, Yale University, and MIT and judges for the MIT $100K entrepreneurship competition. Hyuk-Jeen earned his Ph.D. in electrical engineering, focusing on Microelectromechanical Systems (MEMS) from University of Illinois at Urbana-Champaign. He earned his MBA from Yale School of Management. He holds a B.S. in mechanical engineering, B.A in economics and M.E in electrical engineering, all from Cornell University.
Skip Fleshman (Board Observer)
Skip Fleshman has been at Asset Management Ventures (“AMV”) since 2002 and is actively investing in companies that focus on digital health, mobile and data analytics.Skip was an officer in the United States Air Force where he first served as a fighter pilot flying the F-16. He flew 37 combat missions during Operation Desert Storm and also served as the wing expert in electronic combat systems and programs.
He then founded and served as COO of BGI which develops software for flight simulators and training solutions for the aviation industry. He received a Bachelor of Science degree in Mechanical Engineering from the University of California at Davis. Skip was a Sloan Fellow and received an M.S. in Management from the Stanford University Graduate School of Business. Skip is an advisor to Stanford’s StartX, Rock Health, Boston Children’s Hospital and the Hiller Aviation Museum.